All In Biotech

Drug Trial Radar · NCT03196284

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Last checked: Nov 20, 2026Latest source record: Oct 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

26

Actual

Start

Aug 10, 2017

Primary completion

Sep 19, 2018

Study completion Jan 31, 2020

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.

Conditions

  • Congenital Bleeding Disorder
  • Haemophilia A With Inhibitors
  • Haemophilia B With Inhibitors

Interventions

  • ConcizumabDrug

    A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase

  • Eptacog alfaDrug

    A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Bleeding EpisodesTime frame: During at least 24 weeks from treatment onset (week 0)

Locations

22 sites in 14 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Indianapolis, Indiana

  • Novo Nordisk Investigational Site

    Iowa City, Iowa

  • Novo Nordisk Investigational Site

    Vienna, Austria

  • Novo Nordisk Investigational Site

    Toronto, Ontario, Canada

  • Novo Nordisk Investigational Site

    Zagreb, Croatia

  • Novo Nordisk Investigational Site

    Århus N, Denmark

  • Novo Nordisk Investigational Site

    Athens, Greece

  • Novo Nordisk Investigational Site

    Tel HaShomer, Israel

  • Novo Nordisk Investigational Site

    Florence, Italy

  • Novo Nordisk Investigational Site

    Milan, Italy

  • Novo Nordisk Investigational Site

    Aichi, Japan

  • Novo Nordisk Investigational Site

    Nara, Japan

  • Novo Nordisk Investigational Site

    Tokyo, Japan

  • Novo Nordisk Investigational Site

    Georgetown, Penang, Malaysia

  • Novo Nordisk Investigational Site

    Kota Kinabalu, Malaysia

  • Novo Nordisk Investigational Site

    Madrid, Spain

  • Novo Nordisk Investigational Site

    Seville, Spain

  • Novo Nordisk Investigational Site

    Solna, Sweden

  • Novo Nordisk Investigational Site

    Lviv, Ukraine

  • Novo Nordisk Investigational Site

    London, United Kingdom

  • Novo Nordisk Investigational Site

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.